Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMDNASDAQ:EDSANASDAQ:ERNAOTCMKTS:OASMY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$0.65+0.9%$0.55$0.40▼$1.17$13.50M2.14505,236 shs74,979 shsEDSAEdesa Biotech$1.95-2.0%$2.19$1.55▼$5.59$13.70M0.55491,601 shs11,306 shsERNAEterna Therapeutics$0.18+0.1%$0.20$0.15▼$2.63$11.23M5.612.82 million shs357,413 shsOASMYVivesto$0.02$0.02$0.01▼$0.05$3.59M22.722,050 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.87%-13.32%+18.18%+36.84%-20.73%EDSAEdesa Biotech-2.01%-2.01%-18.20%-15.95%-57.52%ERNAEterna Therapeutics+0.11%-21.74%-9.09%-38.88%-90.84%OASMYVivesto0.00%0.00%0.00%-50.00%-59.92%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIMDAinos0.4852 of 5 stars0.02.00.00.02.30.80.6EDSAEdesa Biotech3.1131 of 5 stars3.55.00.00.02.21.70.6ERNAEterna Therapeutics0.5771 of 5 stars0.03.00.00.00.81.70.6OASMYVivestoN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 0.00N/AN/AN/AEDSAEdesa Biotech 3.00Buy$21.00976.92% UpsideERNAEterna Therapeutics 0.00N/AN/AN/AOASMYVivesto 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest OASMY, EDSA, ERNA, and AIMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025EDSAEdesa BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$21.00 ➝ $21.00(Data available from 6/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$106.21K127.08N/AN/A$5.23 per share0.12EDSAEdesa BiotechN/AN/AN/AN/A$0.18 per shareN/AERNAEterna Therapeutics$535K20.98N/AN/A$0.41 per share0.44OASMYVivesto$100K35.87N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$13.77M-$1.29N/A∞N/AN/A-75.16%-50.22%8/4/2025 (Estimated)EDSAEdesa Biotech-$6.17M-$1.59N/AN/AN/AN/A-233.69%-124.14%8/8/2025 (Estimated)ERNAEterna Therapeutics-$21.67M-$8.31N/A∞N/A-7,513.88%N/A-117.48%8/11/2025 (Estimated)OASMYVivesto-$35.35MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest OASMY, EDSA, ERNA, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q2 2025EDSAEdesa Biotech-$0.30-$0.30N/A-$0.30N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 million3/7/2025Q4 2024AIMDAinosN/A-$0.26N/A-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AEDSAEdesa BiotechN/AN/AN/AN/AN/AERNAEterna TherapeuticsN/AN/AN/AN/AN/AOASMYVivestoN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.501.371.33EDSAEdesa BiotechN/A1.090.91ERNAEterna TherapeuticsN/A0.480.48OASMYVivestoN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AEDSAEdesa Biotech5.50%ERNAEterna Therapeutics70.55%OASMYVivestoN/AInsider OwnershipCompanyInsider OwnershipAIMDAinos10.39%EDSAEdesa Biotech22.60%ERNAEterna Therapeutics1.50%OASMYVivestoN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos4020.76 million12.62 millionNot OptionableEDSAEdesa Biotech207.02 million2.60 millionNot OptionableERNAEterna Therapeutics1062.36 million5.17 millionNo DataOASMYVivesto20179.35 millionN/ANot OptionableOASMY, EDSA, ERNA, and AIMD HeadlinesRecent News About These CompaniesVivesto AB Reports Strategic Progress in Q1 2025May 10, 2025 | tipranks.comVivesto AB DRC (OASMY)October 19, 2024 | investing.comAstellas takes $170m charge as it drops DMD gene therapiesSeptember 5, 2024 | pharmaphorum.comVivesto AB ADR OASMYJanuary 20, 2024 | morningstar.comVivesto AB (VIVE) NPVOctober 13, 2023 | hl.co.ukVivesto AB (OASMY) Stock Historical Prices & Data - Yahoo FinanceAugust 29, 2023 | finance.yahoo.comOMX Stockholm Pharmaceuticals and Biotechnology GI (SX201030GI)July 19, 2023 | investing.comOMX Stockholm Health Care GI (SX20GI)June 4, 2023 | investing.comGlobal Pet Cancer Therapeutics Market Report to 2027 - Featuring Zoetis, AB Science, Karyopharm Therapeutics, Vivesto and Merial Among OthersFebruary 26, 2023 | benzinga.comOasmia Pharmaceutical AB ADR (OASMY)January 11, 2022 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueBigBear.ai: Risky AI Stock or Defense Tech Opportunity?By Jeffrey Neal Johnson | May 28, 2025View BigBear.ai: Risky AI Stock or Defense Tech Opportunity?These 3 Stocks Are Buying Back Billions in SharesBy Leo Miller | June 3, 2025View These 3 Stocks Are Buying Back Billions in SharesThese ETFs Provide Easy Exposure to Growing International MarketsBy Nathan Reiff | May 24, 2025View These ETFs Provide Easy Exposure to Growing International Markets3 Alternative Asset Managers Are Raising Dividends by 5% to 25%By Leo Miller | May 13, 2025View 3 Alternative Asset Managers Are Raising Dividends by 5% to 25%OASMY, EDSA, ERNA, and AIMD Company DescriptionsAinos NASDAQ:AIMD$0.65 +0.01 (+0.87%) As of 06/4/2025 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Edesa Biotech NASDAQ:EDSA$1.95 -0.04 (-2.01%) As of 06/4/2025 03:51 PM EasternEdesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.Eterna Therapeutics NASDAQ:ERNA$0.18 +0.00 (+0.11%) As of 06/4/2025 04:00 PM EasternEterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Vivesto OTCMKTS:OASMY$0.02 0.00 (0.00%) As of 06/3/2025Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robinhood Stock Keeps Giving Investors Reasons To Buy CrowdStrike Stock Dips on Guidance Miss: It May Rebound Fast Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Intuit's AI Boom: Stock Soaring, But Should Investors Hit Pause? Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
